Advertisement

Lipoprotein(a) as a risk factor associated with ischemic heart disease: Ouro Preto Study

      Abstract

      Evidences suggest that lipoprotein(a) [Lp(a)] is an important risk factor for cardiovascular disease. However, literature has been controversial in confirming its role as an independent risk factor for cardiovascular disease. The objective of the present study is to evaluate the association between serum levels of Lp(a) and ischemic heart disease as well as other cardiovascular risk factors in a population-based study conducted on a local cohort of the Brazilian population.
      Lp(a) serum levels were measured in 400 individuals selected from a larger sample of a populational survey carried out in Ouro Preto, a city in the southeast of Brazil. Lipid profile, fasting blood glucose, anthropometric and clinical parameters were analyzed.
      Lp(a) levels were significantly associated with the presence of ischemic heart disease. In relation to other cardiovascular risk factors, it was verified that Lp(a) levels were statistically associated with age, total cholesterol, LDL-cholesterol and percentage of body fat determined by bioelectric impedance. Lp(a) was also highly associated with the Framingham risk score (p = 0.003). In a multivariate analysis two significant interactions were revealed; one involving ischemic heart disease, sex and age and other associating ischemic heart disease, age and total cholesterol.
      In summary, in the present analysis Lp(a) serum levels were correlated with the occurrence of ischemic heart disease and other cardiovascular risk factors.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • OPAS (Organización Panamericana de la Salud)
        Tendencias demográficas y de mortalidad en la región de las Américas, 1980–2000.
        Bol Epidemiol. 2002; 23: 1-4
        • Armaganijan D.
        • Batlouni M.
        Impacto dos fatores de risco tradicionais.
        Rev Soc Cardiol Estado de São Paulo. 2000; 10: 686-693
        • Harjai K.J.
        Potencial new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress and fibrinogen.
        Ann Intern Med. 1999; 131: 376-386
        • Koschinsky M.L.
        • Marcovina S.M.
        Structure–function relationships in apolipoprotein (a): insights into lipoprotein(a) assembly and pathogenicity.
        Curr Opin Lipidol. 2004; 15: 167-174
        • Koschinsky M.L.
        • Marcovina S.M.
        Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside.
        Curr Opin Lipidol. 2003; 14: 361-366
        • Anglés-Cano E.
        Structural basis for the pathophysiology of lipoprotein (a) in the athero-thrombotic process.
        Braz J Med Biol Res. 1997; 30: 1271-1280
        • Catalano M.
        • Perilli E.
        • Carzaniga G.
        • et al.
        Lp(a) in hypertensive patients.
        J Hum Hypertens. 1998; 12: 83-89
        • Gazzaruso C.
        • Bruno R.
        • Pujia A.
        • et al.
        Lipoprotein(a), apolipoprotein(a) polymorphism and coronary atherosclerosis severity in type 2 diabetic patients.
        Int J Cardiol. 2006; 108: 354-358
        • Habib S.S.
        • Aslam M.
        Lipids and lipoprotein(a) concentrations in Pakistani patients with type 2 diabetes mellitus.
        Diab Obes Metab. 2004; 6: 338-343
        • Boyer H.
        • Gennes J.L.
        • Truffert J.
        • et al.
        Lp(a) levels in different types of dyslipidemia in the French population.
        Atherosclerosis. 1990; 85: 61-69
        • Wang J.
        • Zhang C.
        • Chen D.
        • Liu X.
        • Feng X.
        Lipoprotein (a) and its immune complexes in dyslipidemic subjects.
        Clin Biochem. 2004; 37: 710-713
        • Lamon-Fava S.
        • Wilson P.
        • Schaefer E.J.
        Impact of body mass index on coronary heart disease risk factors in men and women.
        Arterioscler Thromb Vasc Biol. 1996; 16: 1509-1515
        • Chien K.-L.
        • Lee Y.-T.
        • Sung F.-C.
        • et al.
        Lipoprotein (a) level in the population in Taiwan: relationship to sociodemographic and atherosclerotic risk factors.
        Atherosclerosis. 1999; 143: 267-273
        • Akanji A.
        • Al-Shayji I.
        • Kumar P.
        Metabolic and anthropometric determinants of serum Lp(a) concentrations and apo(a) polymorphism in a healthy Arab population.
        Int J Obes. 1999; 23: 855-862
        • IBGE (Instituto Brasileiro de Geografia e Estatística)
        Contagem populacional.
        1996
      1. Mion Júnior D. (Coord.). IV Diretrizes Brasileiras de Hipertensão Arterial. Sociedade Brasileira de Hipertensão, Sociedade Brasileira de Cardiologia, Sociedade Brasileira de Nefrologia. http://publicacoes.cardiol.br/consenso/2004/Diretriz%20HA%20ENG.pdf; September 2002.

        • World Health Organization
        WHO Expert Committee on Physical Status: the use and interpretation of anthropometry physical status.
        World Health Organization, Geneva1995 ([WHO Technical Report Series, vol. 854])
        • Han T.S.
        • Van Leer E.M.
        • Seidell J.C.
        • Lean M.E.J.
        Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample.
        BMJ. 1995; 311: 1401-1405
        • Pereira R.A.
        • Sichieri R.
        • Marins V.M.R.
        Razão cintura/quadril como preditor de hipertensão arterial.
        Cad Saúde Pública. 1999; 15: 333-344
        • Gallagher D.
        • Heymsfield S.B.
        • Heo M.
        • et al.
        Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index.
        Am J Clin Nutr. 2000; 72: 694-701
      2. Instruction manual body fat monitor Omron BF 300, available at http://www.omron-healthcare.com/ [accessed on 20/03/2003].

      3. National Institutes of Health Third Report of the National Cholesterol Education Program. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Cholesterol Education Program. National Heart, Lung, and Blood Institute. National Institutes of Health. Washington DC, US. NHI Publication. 01-3670; 2001. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf (March 25, 2000).

      4. Sociedade Brasileira de Diabetes Consenso Brasileiro de Conceitos e Condutas para o Diabetes Mellitus Recomendação da Sociedade Brasileira de Diabetes para a Prática Clínica. Federação Internacional de Diabetes/Associação para a América do Sul e Caribe October; 2000. http://www.anad.org.br/consenso.htm (May 12, 2001).

        • Leino A.
        • Impivaara O.
        • Kaitsaari M.
        • Järvisalo J.
        Serum concentrations of apolipoprotein A-1, Apolipoprotein B and lipoprotein(a) in a population sample.
        Clin Chem. 1995; 41: 1633-1636
        • Utermann G.
        Genetic architecture and evolution of the lipoprotein(a) trait.
        Curr Opin Lipidol. 1999; 10: 133-141
        • Frankenfield D.C.
        • Rowe W.A.
        • Cooney R.N.
        • Smith J.S.
        • Becker D.
        Limits of body mass index to detect obesity and predict body composition.
        Nutrition. 2001; 17: 26-33
        • Després J.P.
        The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients’ risk.
        Obes Res. 1998; 6: 8-17
        • Sattar N.
        • Tan C.
        • Han T.
        • et al.
        Associations of indices of adiposity with atherogenic lipoprotein subfractions.
        Int J Obes. 1998; 22: 432-439
        • Sanz E.J.
        • Cazurro A.M.
        • Bellido A.L.
        • Martin I.M.L.
        Cigarette consumption and lipoprotein(a) concentrations.
        Clin Chem. 1996; 42: 479
        • Agewall S.
        • Fagerberg B.
        Lipoprotein (a) was an independent predictor for major coronary events in treated hypertensive men.
        Clin Cardiol. 2002; 25: 287-290
        • Luc G.
        • Bard J.M.
        • Arveiler D.
        • et al.
        Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study.
        Atherosclerosis. 2002; 163: 377-384
        • Ariyo A.A.
        • Thach C.
        • Tracy R.
        Lp(a) lipoprotein, vascular disease, and mortality in the elderly.
        N Engl J Med. 2003; 349: 2108